Indication
Systemic Lupus Erythematosus
The Systemic Lupus Erythematosus pipeline: 55 tracked drugs, 4 approved for this indication.
4 approved / phase 45 Phase 312 Phase 25 Phase 1/221 Phase 18 preclinical / unstaged
Compare the share prices of listed companies in Systemic Lupus Erythematosus →
Total attributable cost
$4.5B
$22,000/patient
Drug spend
$1.6B
$7,600/patient
35% of total cost is drugs
All adult and pediatric SLE; 2018 population estimate · US